Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6265270 | 1.00 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6265276 | 1.00 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6270193 | 0.84 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6270188 | 0.84 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8312217 | 0.79 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5215225 | 0.73 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6265060 | 0.71 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5215236 | 0.70 | NUDT1 (0.30) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5785797 | 0.61 | SMN1; SMN2 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5875832 | 0.61 | CDK2 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005095365-A1 | OXAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222227-A1 | Oxazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222227-A1 | Oxazole-amine compounds for the treatment of neurodegenerative disorders | PSEN1, APP, BACE1 | PSEN1 1/4885PSEN2 5/4885APH1B 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.